Alaunos Therapeutics
TCRT
140 hedge funds and large institutions have $410M invested in Alaunos Therapeutics in 2019 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 52 increasing their positions, 26 reducing their positions, and 10 closing their positions.
180% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 10
100% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 26
70% more capital invested
Capital invested by funds: $241M → $410M (+$168M)
13% more funds holding
Funds holding: 124 → 140 (+16)
0.03% more ownership
Funds ownership: 0.26% → 0.29% (+0.03%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
37% less call options, than puts
Call options by funds: $8.42M | Put options by funds: $13.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$10.5M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.35M |
| 3 |
DCM
Discovery Capital Management
South Norwalk,
Connecticut
|
+$4.56M |
| 4 |
Nuveen
Charlotte,
North Carolina
|
+$3.19M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$2.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$1.28M |
| 2 |
SC
Sculptor Capital
New York
|
-$1.01M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$752K |
| 4 |
MIM
MetLife Investment Management
Whippany,
New Jersey
|
-$542K |
| 5 |
IAM
Iridian Asset Management
Westport,
Connecticut
|
-$369K |
TCRT Hedge Fund Activity: Q2 2019 in Review
140 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q2 2019, worth a combined $410M — up 70% from $241M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new TCRT positions and 10 closed out — a net gain of 18 holders — while 52 added to existing stakes and 26 trimmed.
The largest buyer was BlackRock, adding an estimated $10.5M. The largest seller was Bank of America, cutting an estimated $1.28M.
- 140 institutional investors held Alaunos Therapeutics (TCRT) as of Q2 2019, up from 124 in Q1 2019.
- Funds reported $410M of Alaunos Therapeutics stock for Q2 2019, up 70% quarter-over-quarter.
- 28 funds opened new Alaunos Therapeutics positions in Q2 2019 and 10 closed out, a net change of +18 holders.
- The largest Alaunos Therapeutics buyer in Q2 2019 was BlackRock, an estimated $10.5M added.
- The largest Alaunos Therapeutics seller in Q2 2019 was Bank of America, an estimated $1.28M sold.
Based on aggregated 13F filings for Q2 2019.